RO Roche Holding AG

Find insight on Roche Holding, AstraZeneca’s investment in Summit Therapeutics, and more in the latest Market Talks covering Health Care.

Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.

The drugmaker said clinical-trial data suggested the medicine, emugrobart, wouldn’t hit internal targets.

Roche (USOTC:RHHBY) plans to develop autonomous artificial intelligence-driven laboratories as part of its research and development activities, the Swiss pharmaceutical company said Monday. Aviv Regev, executive vice president of Genentech Research and Early Development, said Roche is pursuing “AI independence” in research and development and has started constructing autonomous AI-driven laboratories.

Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and...

Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications

Roche joins Sanofi on the list of big pharma companies that are betting on Earendil’s AI-powered drug discovery platform.

Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational

Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.

While remigromig is non-inferior to Lucentis in terms of efficacy, questions around its tolerability remain.

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...

Sefaxersen reduced proteinuria at 37 weeks, while kidney function and failure outcomes require longer observation.

1018 ET – Roche Holding is expected to move quickly to file for an accelerated approval for its sefaxersen drug candidate, a direct competitor to Novartis’s Fabhalta, RBC Capital Markets analysts say. The Swiss drugmaker reported positive interim results for a late-stage study of sefaxersen in autoimmune disease IgA nephropathy and the company had previously said it hoped the data would lead to an accelerated approval, consistent with the Fabhalta precedent, RBC says. “We think the muted reaction in [Roche] shares downplays the impact of a positive early interim readout from this study in an indication where we model [1.5 billion Swiss francs] in 2034 sales,” the analysts say in a research note.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.